The department of health & human services’ office of inspector general (hhs oig) and u.s Department of justice (doj) have published important guidance and recommendations for pharmaceutical companies to develop and implement effective compliance programs. Read on for actionable steps healthcare providers should consider implementing in 2024, as well as key themes derived from the oig document that should guide compliance efforts. Oig intends to publish the first two icpgs, focusing on medicare advantage and nursing facilities, in 2024, and anticipates issuing compliance guidance for hospitals and clinical laboratories in its next two icpgs. November 6, 2024, marked one year since the office of inspector general (oig) released its general compliance program guidance (gcpg). Oig indicated that specific compliance guidance for subsectors (e.g., lab, snf) will be rolled out starting 2024, but until then the identified risk areas in existing oig compliance guidance should be considered for inclusion in the risk assessment
Oig developed cpgs as voluntary, nonbinding guidance documents to encourage the development and use of internal controls to monitor adherence to applicable statutes,
OPEN
